Evan Pagano¹, Benjamin Frank¹, James Jaggers², Mark Twite³, Tracy T. Urban⁴, Jelena Klawitter^2,#, Jesse Davidson^1,#,*

Congenital Heart Disease, Vol.15, No.4, pp. 251-265, 2020, DOI:10.32604/CHD.2020.012219

Abstract Objectives: (1) To measure the global shift in the metabolome in hypoxemic versus non-hypoxemic infants with congenital heart disease; (2) To identify metabolites and metabolic pathways that are altered in hypoxemia. Study Design: Analysis of serum samples obtained prior to cardiopulmonary bypass from 82 infants ≤120 days old with congenital heart disease requiring surgery at Children’s Hospital Colorado. Infants were divided into groups based on preoperative oxygen saturations: non-hypoxemic (>92%), mild hypoxemia (85–92%), and severe hypoxemia (<85%). Tandem mass spectrometry was used to analyze 165 targeted metabolites. Partial least squares discriminant analysis and t-tests were used to determine differences among… More >

Dong Zhang^1,#, Lingxia Tong^2,#, Qingjun Wang¹, Yunfeng Cao³, Yu Gao¹, Donghua Yang¹, Tianhao Bao^4,5, Zhitu Zhu^1,*

Oncologie, Vol.22, No.2, pp. 75-82, 2020, DOI:10.32604/oncologie.2020.012376

Abstract Predicting the onset and metastasis of early tumor is the primary means of improving lung cancer prognosis. The purpose of this study was to identify the ability of plasma metabolomics combined with blood markers to establish benign lung disease versus lung cancer regression models. Blood samples were collected from 174 lung cancer patients, 350 benign lung disease patients and 100 healthy volunteers and the metabolites were analyzed by mass spectrometry. The target metabolites consisted of 23 amino acids, 26 acylcarnitines and 45 conventional blood markers. A regression analysis model was established based on 12 metabolites and five blood markers selected… More >